Keywords
Teclistamab
Bispecific Antibody
How to Cite
Abstract
Multiple myeloma (MM) remains an incurable disease despite improvements in treatment options that have been developed recent years. B cell maturation antigen (BCMA) is predominantly expressed on B lineage cells and represents a promising new therapeutic target for relapsed re-fractory MM (RRMM). Teclistamab (TECVAYLI) is the first bispecific T cell (CD3) redirecting antibody against BCMA (Figure 1) approved by the US Food and Drug Administration (FDA) in 2022 for patients with RRMM on 3 prior lines of treatment, including Proteasome Inhibitors (PI), Immunomodulators (IMIDS), Monoclonal Antibodies (mAb). ICANS (immune effector cell-associated neurotoxicity), CRS (cytokine release syndrome), and hypogammaglobulinemia infections are the most common adverse effects.
References
Kodandaram Pillarisetti, Gordon Powers,et al.. Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Advances(2020). Vol 4. DOI 10.1182/bloodadvances.2020002393.
Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, et al.. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. (2012) 158:727–38. doi: 10.1111/j.1365-2141.2012.09241.x
Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, et al. Expresión objetivo, generación, actividad preclínica y farmacocinética del anticuerpo biespecífico de células BCMA-T EM801 para el tratamiento del mieloma múltiple. Célula cancerosa. 2017; 31 : 396–410. doi: 10.1016/j.ccell.2017.02.002.
Verkleij CP, Frerichs KA, Broekmans M, et al. Bispecific T-cell retargeting antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget. 2020;11(45):4076. doi:10.18632/onco.
Mateos M-V, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refrac-tory multiple myeloma. Leukemia 2022;36:1371-1376.
Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Teclistamab, a B-cell maturation anti-gen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 2021;398:665-674.
Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al.. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. (2022) 387:495–505. doi: 10.1056/NEJMoa2203478
Van de Donk NWCJ, Garfall AL, Benboubker L, Uttervall K, Groen K, Rosiñol L, et al.. Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1. J Clin Oncol. (2023) 41:8033. doi: 10.1200/JCO.2023.41.16_suppl.8033
Searle E, Quach H, Wong SW, Costa LJ, Hulin C, Janowski W, et al.. Teclistamab in combina-tion with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: re-sults from one cohort of MajesTEC-2, a Phase1b, multicohort study. Blood. (2022) 140:394–6. doi: 10.1182/blood-2022-159711.
Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004; 103(2):689-694.
Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000.
Friedrich MJ, Neri P, Kehl N, et al. The preexisting T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41(4):711-725.e6
Holly Lee, Paola Neri, and Nizar J. Bahlis, BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance. Blood 28 March 2024 | Vol 143, Number 13
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar